(AOF) – Valneva (- 19.50% to 6.53 euros)
Valneva finished at the bottom of the index. The Franco-Austrian vaccine manufacturer has ended its collaboration with IDT Biologika, confirming the end of its Covid adventure. The German biotech manufactured the active ingredient of Valneva’s vaccine against Covid, VLA2001. Or the latter did not receive the achievement. Orders have been so low in recent months that Valneva decided in July to suspend production. A rational but appropriate decision in the short term.
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. subject to its gross negligence, OPTION FINANCES SAS and its contributors do not in any way resist the absence of error and defects, even hidden ones, nor the exhaustive character or the lack of conformity to any use of these data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember on the financial markets.